Zealand Pharma

Copenhagen, 2015-03-21 10:11 CET (GLOBE NEWSWIRE) -- 21 March 2015 - Zealand
Pharma A/S (Nasdaq OMX Copenhagen A/S: ZEAL) (“Zealand”) announces that the
company’s share capital has been increased by nominal DKK 120,833 divided into
120,833 new shares with a nominal value of DKK 1 each. The increase is a
consequence of the exercise of employee warrants granted under three of the
company's warrant programs as described in the company’s Articles of
Association.

The subscription price is DKK 50.27 per share for 90,807 of the new shares of
nominal DKK 1 and DKK 77.00 per share for 30,026 of the new shares of nominal
DKK 1. The total proceeds to Zealand from the capital increase amounts to DKK
6,876,870.

Each new share of nominal DKK 1 carries one vote at Zealand’s general meetings.
The new shares give rights to dividend and other rights from the time of the
warrant holder's exercise notice.

The new shares will be listed on NASDAQ OMX Copenhagen A/S following
registration of the capital increase with the Danish Business Authority, upon
which the share capital of Zealand will be nominal DKK 23,313,880 divided into
23,313,880 shares with a nominal value of DKK 1 each.

The content of this announcement has no impact on the company’s financial
outlook for 2015.

Pursuant to Section 28a of the Danish Securities Trading Act, Zealand discloses
information on transactions with the company’s shares and related
securities by executives and their related parties. In connection with the
warrants exercise, Zealand has received information on the following
transaction for disclosure:

Name: Keld Fosgerau

Reason: Senior Vice President for Research (interim)

Issuer: Zealand Pharma A/S

Designation: Shares

ISIN Code: DK0060257814

Transaction: Exercise of warrants

Trading Date: 20 March 2015

Market: Nasdaq OMX Copenhagen A/S

Number: 11,250

Price: DKK 77.00

Market value: DKK 866,250

                                  ?????

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer

Tel: +45 51 67 61 28, email: [email protected]

Hanne Leth Hillman, Senior Vice President for Communications and Investor
Relations

Tel: +45 50 60 36 89, email: [email protected]

About Zealand Pharma

Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology
company based in Copenhagen, Denmark. Zealand has leading expertise in the
discovery, design and development of novel peptide medicines and possesses
in-house competences in clinical trial design and management with a therapeutic
focus on metabolic diseases and acute care indications. The company is
advancing a pipeline of novel wholly-owned medicines alongside a partnered
product and development portfolio.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1
agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as
Lyxumia® and in Phase III development as a single-injection combination with
Lantus® (LixiLan), both under a global license agreement with Sanofi. US
regulatory submission of Lyxumia® is planned for Q3 2015 and US/EU regulatory
submissions for LixiLan in Q4 2015.

Zealand’s wholly-owned products include danegaptide (prevention of Ischemic
Reperfusion Injury) in Phase II and the stable glucagon product, ZP4207
(treatment of severe hypoglycemia) in Phase I as well as several preclinical
peptide therapeutics. Partnering represents an important component of strategy
to leverage in-house expertise, share development risk in large clinical
trials, provide funding and commercialize the company’s products. Zealand
currently has global license agreements and partnerships with Sanofi, Helsinn
Healthcare, Boehringer Ingelheim and Eli Lilly.

For further information: www.zealandpharma.com Follow us on Twitter
@ZealandPharma

AI Terminal